| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4179826 | Biological Psychiatry | 2009 | 9 Pages |
Abstract
These results indicate that isradipine, at a therapeutically relevant dose, might represent a treatment option for preventing L-DOPA-induced dyskinesia in PD.
Related Topics
Life Sciences
Neuroscience
Biological Psychiatry
Authors
Stefan Schuster, Evelyne Doudnikoff, Daniella Rylander, Amandine Berthet, Incarnation Aubert, Carina Ittrich, Bertrand Bloch, M. Angela Cenci, D. James Surmeier, Bastian Hengerer, Erwan Bezard,